Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 (Engensis) in Critical Limb Ischemia
NCT01064440Phase 2Completed
- Sponsor
- Helixmith
- Start
- Jul 2010
- Primary completion
- Aug 2013
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 2
01
Overview
A Phase 2 trial of Engensis in critical limb ischemia (CLI), sponsored by Helixmith. Started Jul 2010; status: completed.
02
Drugs
Engensis
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT01064440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064440.